Evaxion (EVAX) Q4 2025 earnings review
Cash Runway Extended, Focus Shifts to Execution and Autoimmune Expansion
Evaxion ended 2025 in its strongest financial position to date, with $23.2M in cash extending its runway into H2 2027. The historic $7.5M MSD licensing deal for EVX-B3 drove full-year revenue and temporarily swung Q3 to profitability, but Q4 saw revenue drop back to zero and net loss widen to $5.9M due to non-cash warrant liabilities. The core narrative remains pipeline execution: the personalized cancer vaccine EVX-01 delivered unprecedented two-year durability data, and the company is strategically expanding its AI-Immunology platform into autoimmune diseases. However, MSD's quiet decision not to exercise its option on the EVX-B2 gonorrhea candidate represents a notable setback, placing intense pressure on management to secure new partnerships in a challenging macro environment.
🐂 Bull Case
MSD's payment of $7.5M to license EVX-B3 marks the first-ever in-licensing of an AI-discovered vaccine candidate by a major pharma company. This permanently validates the AI-Immunology platform's commercial viability.
EVX-01 Phase 2 data showed the objective response rate actually improved from 69% at one year to 75% at two years, with 92% of patients showing durable clinical benefit. This robust profile significantly strengthens the pitch to potential late-stage partners.
🐻 Bear Case
MSD chose not to exercise its option on the EVX-B2 gonorrhea candidate. This deprives Evaxion of a near-term milestone payment and forces the company to find a new partner for the asset from scratch.
After the Q3 MSD milestone, Q4 revenue immediately reverted to zero. The company's financial health is entirely dependent on striking new, unpredictable partnership deals before the cash runway expires.
⚖️ Verdict: ⚪
Neutral. The extended cash runway and outstanding EVX-01 clinical data provide a solid foundation. However, MSD's rejection of EVX-B2 highlights the binary risks inherent in their partnership-dependent model, and the company must now prove it can strike new deals in a tight macro environment.
Key Themes
MSD Declines EVX-B2 Option
Reversing. While management celebrated the EVX-B3 license with MSD earlier in the year, the Q4 update quietly confirmed that MSD chose not to exercise its option on the EVX-B2 gonorrhea candidate. Evaxion retains full rights, but this represents a significant setback. It deprives the company of a near-term milestone payment and shifts the burden back to Evaxion to market the asset independently.
AI-Immunology Expands into Autoimmune Diseases
Accelerating. A major strategic update is the expansion of the AI-Immunology platform to target autoimmune diseases (AIDs). Management plans to launch this new application in H2 2026. This is a brilliant strategic pivot: AIDs represent a massive market with high unmet needs, and expanding the platform’s scope significantly increases the pool of potential partnership targets beyond the existing oncology and infectious disease boundaries.
EVX-01 Delivers Unprecedented Two-Year Data
Stable. The personalized cancer vaccine EVX-01 remains the crown jewel of the clinical pipeline. Two-year Phase 2 data in advanced melanoma showed a 75% Objective Response Rate (12 of 16 patients) and a 92% durable clinical benefit. Crucially, 81% of targeted neoantigens generated specific T-cell responses. This durable efficacy provides the essential clinical validation needed to secure a late-stage development partner.
EVX-04 Advances Toward the Clinic
Accelerating. The off-the-shelf AML vaccine EVX-04, which targets endogenous retrovirus (ERV) antigens from the 'dark genome', is progressing rapidly. Following positive data at ASH 2025 showing all 16 ERV fragments elicit immune responses, the company is preparing for a Phase 1 regulatory filing in H2 2026. This validates the platform's ability to discover non-conventional targets and adds a second clinical-stage oncology asset.
Non-Cash Items Distort Bottom Line
Reversing. Despite management's touting of financial strengthening, Q4 Net Loss actually worsened by 63% YoY to $5.9M. This directly contradicts the positive financial narrative on the surface. However, the widening loss was entirely driven by a $2.7M finance expense related to the remeasurement of derivative liabilities from investor warrants. Operating loss remained perfectly stable at $4.1M. This non-cash accounting noise will likely continue to obscure actual cash burn performance.
Macro Environment Pressures Deal Execution
Stable. Evaxion is highly dependent on out-licensing its assets. Management has frequently noted throughout 2025 that challenging financial markets and regulatory uncertainty are impacting deal execution across the biotech sector. With MSD passing on EVX-B2, Evaxion is now forced to market both EVX-B2 and EVX-01 in this constrained macro environment. Time is on their side, but the broader industry reluctance to close early-stage deals remains a structural headwind.
Strict Cost Discipline Maintained
Stable. Despite expanding its pipeline with EVX-04 and EVX-B4, Evaxion actually lowered its R&D expenses YoY ($10.0M vs $10.5M). General and administrative expenses also fell to $6.8M from $7.6M. This incredibly lean operational model is crucial for maximizing the runway of its $23.2M cash balance.
Other KPIs
Accelerating. Up sharply from $6.0 million at the end of FY24. The massive improvement was driven by the $7.5M MSD option exercise fee, ATM facility usage, and an EIB debt-to-equity conversion. Total equity similarly rebounded from a negative $1.7M deficit to a positive $17.0M.
Accelerating. A massive leap from $3.3 million in 2024, almost entirely attributable to the historic MSD licensing of EVX-B3. Going forward, MSD will carry all development costs for EVX-B3, while Evaxion remains eligible for up to $592 million in future milestone payments.
Accelerating. A substantial improvement from the $14.7M loss in 2024. The improvement was driven primarily by the MSD revenue injection, but also aided by a $1.3M reduction in combined R&D and G&A expenses.
Guidance
Stable. Management expects cash expenditure to remain identical to 2025 levels. This implies zero YoY growth in cash burn. This reflects extreme cost discipline as the company advances EVX-04 toward the clinic, indicating they will rely heavily on partners to fund larger late-stage trials rather than bloating their own balance sheet.
Accelerating. Following over $30 million in capital influx during 2025 (including the $7.5M MSD option fee and EIB debt conversion), the cash runway has been significantly extended. This removes the near-term financing overhang and provides vital breathing room to negotiate partnerships from a position of strength.
Key Questions
Feedback on EVX-B2
With MSD opting out of the EVX-B2 gonorrhea candidate, what specific feedback did they provide regarding the data package, and how does this alter your partnering strategy for the asset?
Autoimmune Competitive Edge
Autoimmune disease is a highly competitive space. What unique advantages does AI-Immunology offer in discovering AID targets compared to existing, established platforms?
EVX-04 Clinical Funding
Given the planned Phase 1 regulatory filing for EVX-04 in H2 2026, do you intend to fund the initial clinical trial internally, or is securing a partnership a prerequisite before dosing patients?